CD47 and lung cancer: These results suggest that CD47 is a feasible therapy target and that anti-human CD47-blocking antibody may serve as an effective therapeutic agent to inhibit lung cancer growth by enabling macrophages to eliminate both CSCs and their differentiated progeny.